Stay updated on Pembrolizumab in Lymphoma Subtypes Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Subtypes Clinical Trial page
- Check4 days agoChange DetectedPage revision updated to v3.3.4 (replacing v3.3.3); this appears to be a minor site update with no changes to study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded the Maryland location under Locations and updated the page revision to v3.3.3. Removed the Maryland Locations footer item and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check47 days agoChange DetectedRevision: v3.3.2 was added and v3.3.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check62 days agoChange DetectedRemoved the notice about operating status due to a lapse in government funding from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check76 days agoChange DetectedNo significant changes detected between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Lymphoma Subtypes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.